NASDAQ:LEXX

Lexaria Bioscience Q2 2026 Earnings Results & Report

Lexaria Bioscience logo
$4.26 -0.15 (-3.31%)
As of 09:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Lexaria Bioscience beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released April 13, 2026. The company reported EPS of -$0.90 versus the -$1.4250 consensus estimate, while revenue of $20 thousand fell short of the $50 thousand estimate by $30.00 thousand.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Lexaria Bioscience EPS Results

Actual EPS
-$0.90
Consensus EPS
-$1.4250
Beat/Miss
Beat by +$0.5250
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Lexaria Bioscience Revenue Results

Actual Revenue
$20 thousand
Expected Revenue
$50 thousand
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

Lexaria Bioscience's Q4 2026 earnings is estimated for Tuesday, November 24, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 23, 2026 at 12:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Lexaria Bioscience Q2 2026 Earnings FAQ

Lexaria Bioscience (NASDAQ:LEXX) reported earnings of -$0.90 per share for Q2 2026, beating the consensus estimate of -$1.4250. The report was announced on Monday, April 13, 2026.

Lexaria Bioscience reported revenue of $20 thousand for Q2 2026, against a consensus estimate of $50 thousand.

Lexaria Bioscience's next earnings date is estimated for Tuesday, November 24, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexaria Bioscience on the company's earnings history page.

Lexaria Bioscience Earnings Headlines

Lexaria Bioscience (LEXX) Projected to Release Earnings on Tuesday
Trump’s EO to send this $5 stock ripping higher…?
President Trump's December executive order declared space a national security and economic priority, fueling a race among SpaceX, Blue Origin, and others to build massive satellite constellations. One tiny firm holds the patented tech required to transmit satellite data to Earth at scale - and it reportedly powers SpaceX's most profitable division. Shares trade for under 5 dollars. Former JPMorgan wealth manager Ross Givens says it's the most uniquely positioned stock he's seen in 20 years of trading.tc pixel
LEXX: Introducing DehydraTECH 3.0
Lexaria Bioscience advances 12% on Australian tax rebate
See More Lexaria Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Lexaria Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexaria Bioscience and other key companies, straight to your email.

About Lexaria Bioscience

Lexaria Bioscience (NASDAQ:LEXX) is a biotechnology company developing DehydraTECH, a patented technology designed to improve the delivery and absorption of orally administered drugs and other active compounds. The platform incorporates active ingredients into a lipid-based formulation and is being studied for its potential to affect absorption and delivery characteristics.

The company’s research has explored applications in areas including hypertension, diabetes and weight management, epilepsy, and antiviral treatments. These programs are investigational; Lexaria’s work includes laboratory and clinical research rather than a broad portfolio of approved medicines.

Based in British Columbia, Canada, Lexaria focuses on developing and licensing its delivery technology and advancing research with pharmaceutical ingredients. The company has also developed consumer products in the past, including hemp-derived products, but its current activities center on DehydraTECH research and development.

View Lexaria Bioscience Profile